Monopar Therapeutics (MNPR)

Executive Summary

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel radiopharmaceuticals for oncology and a late-stage therapy for Wilson Disease. Leveraging a lean, virtual operating model, the company aims to address significant unmet medical needs in rare diseases and oncology. Its lead radiopharmaceutical candidate, MNPR-101, targets the urokinase plasminogen activator receptor (uPAR), which is overexpressed in multiple solid tumors. The pipeline includes a therapeutic conjugate (MNPR-101-PCTA-177Lu) currently in a Phase 1 dose-escalation trial, and a diagnostic imaging agent (MNPR-101-DFO*-89Zr) also in Phase 1. Both trials are recruiting and represent key value drivers for the company. Monopar's strategy of combining imaging and therapy (theranostics) positions it to potentially offer precision treatment for cancers with high uPAR expression. With a market cap of approximately $390 million, the company is well-funded to advance its programs through initial clinical readouts.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 imaging trial (MNPR-101-DFO*-89Zr) results80% success
• H2 2026Phase 1 therapeutic trial (MNPR-101-PCTA-177Lu) dose-escalation data60% success
• TBDWilson Disease program update (IND filing or Phase 2/3 data)50% success